Fig. 2From: Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPDBenefit–harm curves for 100,000 estimates of the benefit-harm index (each curve) for roflumilast: IR, Incidence rate; IRR, Incidence rate ratioBack to article page